Voyager Therapeutics (VYGR) Tops Q3 EPS by 5c

Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.47), $0.05 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $13.37 million versus the consensus estimate of $7.86 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c